MedTrace Logo

A Retrospective Study of Patients With Leukemia Relapse in the CNS Treated With CAR T Cells

NCT04158011 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 80

Last updated 2019-11-08

No results posted yet for this study

Summary

CAR T cells targeting CD19 have been approved for patients with relapsed or refractory ALL, failing two or more prior protocols. Several institutional-based studies with other CAR T cells targeting CD19 have demonstrated outstanding response rates in patients with refractory disease, and the ability of CAR T cells to clear CNS leukemia. Nevertheless, these cases are sparse and have never been reported collectively.

Here, we aim to retrospectively assess toxicity and long term outcome of patients treated with CAR T cells for CNS relapse of ALL.

Conditions

Sponsors & Collaborators

  • Sheba Medical Center

    lead OTHER_GOV

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-11-06
Primary Completion
2020-03-01
Completion
2021-01-01

Countries

  • Israel

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04158011 on ClinicalTrials.gov